Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging

被引:0
|
作者
Saida, Tsukasa [1 ]
Shikama, Ayumi [2 ]
Mori, Kensaku [1 ]
Ishiguro, Toshitaka [1 ]
Minaguchi, Takeo [2 ]
Satoh, Toyomi [2 ]
Nakajima, Takahito [1 ]
机构
[1] Univ Tsukuba, Dept Radiol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Dept Obstet & Gynecol, Fac Med, Tsukuba, Ibaraki, Japan
关键词
breast cancer; cancer; high-grade serous carcinoma; magnetic resonance imaging; ovary; SOMATIC MUTATIONS; INVASION PATTERNS; FALLOPIAN-TUBE; OVARIAN; BENEFIT; BRCA1; GERMLINE; SURVIVAL; PLATINUM;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To compare MRI findings of high-grade serous carcinoma (HGSC) with and without breast cancer (BRCA) gene variants to explore the feasibility of MRI as a genetic predictor. Methods: We retrospectively reviewed MRI data from 16 patients with BRCA variant-positive (11 patients of BRCA1 and 5 patients of BRCA2 variant-positive) and 32 patients with BRCA variant-negative HGSCs and evaluated tumor size, appearance, nature of solid components, apparent diffusion coefficient (ADC) value, time-intensity curve, several dynamic contrast-enhanced curve descriptors, and nature of peritoneal metastasis. Age, primary site, tumor stage, bilaterality, presence of lymph node metastasis, presence of peritoneal metastasis, and tumor markers were also compared between the groups with the Mann-Whitney U and chi-square tests. Results: The mean tumor size of BRCA variant-positive HGSCs was 9.6 cm, and that of variant-negative HGSCs was 6.8 cm, with no significant difference (P = 0.241). No significant difference was found between BRCA variant-positive and negative HGSCs in other evaluated factors, except for age (mean age, 53 years old; range, 32-78 years old for BRCA variant-positive and mean age, 61 years old; range, 44-80 years old for BRCA variant-negative, P = 0.033). Comparing BRCA1 variant-positive and BRCA2 variant-positive HGSCs, BRCA1 variant-positive HGSCs were larger (P = 0.040), had greater Max enhancement (P = 0.013), Area under the curve (P = 0.013), and CA125 (P = 0.038), and had a higher frequency of lymph node metastasis (P = 0.049), with significance. Conclusion: There was no significant difference in the MRI findings between patients with HGSCs with and without BRCA variants. Although studied in small numbers, BRCA1 variant-positive HGSCs were larger and more enhanced than BRCA2 variant-positive HGSCs with higher CA125 and more frequent lymph node metastases, and may represent more aggressive features.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
  • [1] Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging
    Saida, Tsukasa
    Shikama, Ayumi
    Mori, Kensaku
    Ishiguro, Toshitaka
    Minaguchi, Takeo
    Satoh, Toyomi
    Nakajima, Takahito
    MAGNETIC RESONANCE IN MEDICAL SCIENCES, 2022, : 18 - 26
  • [2] The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas
    Salvador, Shannon
    Gilks, Blake
    Koebel, Martin
    Huntsman, David
    Rosen, Barry
    Miller, Dianne
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (01) : 58 - 64
  • [3] Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas
    Dong, Shixiang
    Yu, Fengsheng
    Liu, Yutong
    Yu, Xiao
    Sun, Xin
    Wang, Wenjie
    Wang, Yankui
    GINEKOLOGIA POLSKA, 2023, 94 (10) : 792 - 798
  • [4] Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas
    Torkildsen, Cecilie Fredvik
    Thomsen, Liv Cecilie Vestrheim
    Sande, Ragnar Kvie
    Krakstad, Camilla
    Stefansson, Ingunn
    Lamark, Eva Karin
    Knappskog, Stian
    Bjorge, Line
    CANCER MEDICINE, 2023, 12 (13): : 14183 - 14195
  • [5] Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases
    Harada, Yurina
    Kubo, Makoto
    Kai, Masaya
    Yamada, Mai
    Zaguirre, Karen
    Ohgami, Tatsuhiro
    Yahata, Hideaki
    Ohishi, Yoshihiro
    Yamamoto, Hidetaka
    Oda, Yoshinao
    Nakamura, Masafumi
    SURGICAL CASE REPORTS, 2020, 6 (01)
  • [6] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
    Vendrell, Julie A.
    Ban, Iulian O.
    Solassol, Isabelle
    Audran, Patricia
    Cabello-Aguilar, Simon
    Topart, Delphine
    Lindet-Bourgeois, Clothilde
    Colombo, Pierre-Emmanuel
    Legouffe, Eric
    D'Hondt, Veronique
    Fabbro, Michel
    Solassol, Jerome
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [7] Characteristics and prognostic significance of incidentally detected cancer cells in uterine specimens of patients with pelvic high-grade serous carcinoma
    Ushigusa, Takeshi
    Yoshida, Hiroshi
    Kuno, Ikumi
    Kojima, Naoki
    Ishikawa, Mitsuya
    Kato, Tomoyasu
    CYTOPATHOLOGY, 2020, 31 (02) : 122 - 129
  • [8] The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas
    Koebel, Martin
    Reuss, Alexander
    du Bois, Andreas
    Kommoss, Stefan
    Kommoss, Friedrich
    Gao, Dongxia
    Kalloger, Steve E.
    Huntsman, David G.
    Gilks, C. Blake
    JOURNAL OF PATHOLOGY, 2010, 222 (02) : 191 - 198
  • [9] Ultrasound characteristics of early-stage high-grade serous ovarian cancer
    Suh-Burgmann, Elizabeth
    Brasic, Natasha
    Jha, Priyanka
    Hung, Yun-Yi
    Goldstein, Ruth B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (04) : 409.e1 - 409.e8
  • [10] Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer
    Chien, Jeremy
    Neums, Lisa
    Powell, Alexis F. L. A.
    Torres, Michelle
    Kalli, Kimberly R.
    Multinu, Francesco
    Shridhar, Viji
    Mariani, Andrea
    FRONTIERS IN ONCOLOGY, 2018, 8